{"created":"2023-05-15T14:51:12.111015+00:00","id":69994,"links":{},"metadata":{"_buckets":{"deposit":"df303fc1-d70a-4047-b404-fd37e3501735"},"_deposit":{"created_by":1,"id":"69994","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"69994"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00069994","sets":["10:28"]},"author_link":["687246","687244","687239","687233","687237","687245","687234","687238","687242","687243","687232","687247","687240","687241","687235","687236"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2009-12-12","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Fibroblast growth factor 2 (FGF2) is known as a cytokine, which plays a part in various steps of neoangiogenesis by promoting angioblast differentiation, cell growth and invasion. When secreted from tumor cells, FGF2 is also responsible for basement membrane dissolution, migration and metastasis. Furthermore, there is an interaction between cancer cells and fibroblasts around the tumor, through the mediation of cytokines produced by the cancer cells and/or fibroblasts. \nPurpose: To elucidate the change of FGF2 expression in tumor cells and stromal cells of cervical cancers during radiotherapy and to examine its function for basement membrane (BM), which is a barrier of invasion, and for microvessels, which are related with radiresistant tumors \nMaterials and methods: One hundred four patients were recruited into this study. The immunohistichemical FGF2 expression in tumor cells (FGF2-T) were examined using biopsy samples taken before or one week after initiation of radiotherapy. We also investigated the protein expression of FGF2 in tumor stroma (FGF2-S), laminin, VEGF, and CD31. \nResults: FGF2&#8211;T significantly increased in midtreatment samples (P < 0.001), and the high ratio (mid/pre) of FGF2-T was significantly related with better prognosis (P = 0.035). Continuous laminin staining on the BM was significantly related with a good response (P = 0.023). Ratio of FGF2 expression correlated positively with pretreatment laminin staining pattern (P = 0.065).The increased VEGF expression by radiotherapy was significantly related with positive FGF2-S expression in pretreatment samples (P = 0.036), however, not related with prognosis or mean vascular density detected by CD31 expression. \nConclusion: In this protein expression analysis, we found FGF2-T expression change as a monitoring marker for the effectiveness of radiotherapy.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第32回日本分子生物学会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中渡, 美也子"}],"nameIdentifiers":[{"nameIdentifier":"687232","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岩川, 眞由美"}],"nameIdentifiers":[{"nameIdentifier":"687233","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大野, 達也"}],"nameIdentifiers":[{"nameIdentifier":"687234","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤, 真吾"}],"nameIdentifiers":[{"nameIdentifier":"687235","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中村, 悦子"}],"nameIdentifiers":[{"nameIdentifier":"687236","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大久保, 悠"}],"nameIdentifiers":[{"nameIdentifier":"687237","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田巻, 倫明"}],"nameIdentifiers":[{"nameIdentifier":"687238","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"今井, 高志"}],"nameIdentifiers":[{"nameIdentifier":"687239","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中渡 美也子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687240","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岩川 眞由美","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687241","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大野 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687242","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 眞吾","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687243","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中村 悦子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687244","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大久保 悠","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687245","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田巻 倫明","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687246","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"今井 高志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"687247","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"放射線治療分割照射子宮頸がん生検材料におけるFGF2発現変化","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"放射線治療分割照射子宮頸がん生検材料におけるFGF2発現変化"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-12-14"},"publish_date":"2009-12-14","publish_status":"0","recid":"69994","relation_version_is_last":true,"title":["放射線治療分割照射子宮頸がん生検材料におけるFGF2発現変化"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:08:02.866328+00:00"}